Tag
A randomized trial in Haiti demonstrates that switching to bictegravir, emtricitabine, and tenofovir alafenamide is non-inferior to ritonavir-boosted protease inhibitors in maintaining viral suppression among second-line HIV therapy patient
This mixed-methods study assesses a novel Adolescent and Young Adult Healthcare Transition (AYA HCT) clinic that achieved high retention but suboptimal viral suppression among youth with HIV, highlighting key strengths and barriers.
A phase 2 trial in South Africa shows that the M72/AS01E-4 TB vaccine is safe and immunogenic for virally suppressed, ART-treated HIV-positive adolescents and adults, supporting its potential to address a key unmet clinical need.
MVA-BN vaccination is safe and effective against mpox in at-risk populations, but reduced protection is noted in people living with HIV. Dose strategies and patient immunological status may affect outcomes.
The PASO-DOBLE trial demonstrated non-inferiority of dolutegravir/lamivudine versus bictegravir/FTC/TAF for maintenance in virologically suppressed HIV-1 adults, with similar efficacy and safety over 48 weeks.
TAF–emtricitabine and dolutegravir-based regimens outperform standard options as second-line ART for African children with HIV, offering improved viral suppression and safety.
Discovery of genetically conserved, mutation-intolerant HIV peptides in rebound virus during analytic treatment interruption highlights new avenues for mRNA vaccine development and functional HIV cure strategies.
A clinical study reveals that trimethoprim-sulfamethoxazole does not significantly improve infant birth weight or related outcomes in HIV-positive pregnancies.
